Dr Kun Wang | Biomaterials | Best Researcher Award

Dr Kun Wang | Biomaterials | Best Researcher Award

Dr. Kun Wang is a renowned medical expert πŸ‘¨β€βš•οΈ specializing in burn and wound repair πŸ”₯🩹. He serves as Director at Weifang People’s Hospital and is a Chief Physician and Master’s Supervisor at Shandong Second Medical University πŸŽ“. With expertise in treating complex burns, chronic wounds, and scars, he pioneers advanced treatments like laser therapy and minimally invasive surgery πŸ’‘πŸ”¬. Dr. Wang leads key research labs on tissue regeneration and has earned prestigious honors including the “Outstanding Physician of Shandong Province” πŸ…. His dedication to medical innovation and education makes him a leading figure in clinical research and patient care in China πŸ‡¨πŸ‡³.

Dr Kun Wang, Weifang People’s Hospital, China

Profile

SCOPUS

Academic Leader πŸŽ“

Dr. Kun Wang is a distinguished academic leader πŸŽ“ in the field of burn and plastic surgery πŸ”₯🧬. He heads the Key Medical Discipline of Shandong Province and Weifang City πŸ₯, and directs the Weifang Key Laboratory of Traditional Chinese Medicine for Sore Repair and Tissue Regeneration πŸŒΏπŸ”¬. His contributions to clinical education and research have earned him top honors, including the 2023 “Outstanding Physician of Shandong Province” and the “Weiwei Craftsman” award πŸ…. Through his leadership, he fosters innovation, mentors young professionals, and elevates standards in medical education and research across China πŸ‡¨πŸ‡³.

Experience 🩺

Dr. Kun Wang brings extensive clinical and academic experience πŸ©ΊπŸ“˜ to the field of burn and wound care. As Director of the Department of Burns and Wound Repair at Weifang People’s Hospital and Chief Physician πŸ‘¨β€βš•οΈ, he leads innovations in burn treatment, chronic wound healing, and scar management πŸ”₯πŸ§ͺ. He also mentors future medical professionals as a Master’s Supervisor πŸŽ“ and heads the Burn Surgery Discipline Group at Shandong Second Medical University. Recognized for his excellence, he was awarded the 2023 β€œOutstanding Physician of Shandong Province” and β€œWeiwei Craftsman” honors πŸ…, showcasing his leadership, dedication, and impact in healthcare innovation 🌟.

Clinical Expert πŸ‘¨β€βš•οΈ

Dr. Kun Wang is a seasoned clinical expert πŸ‘¨β€βš•οΈ in advanced burn and wound care, specializing in treating complex cases such as deep burns, pediatric and geriatric burns, as well as chemical and electrical injuries πŸ”₯πŸ§’πŸ‘΅βš‘. He excels in scar management through minimally invasive surgery, laser therapy, physical therapy, and medications πŸ’‰πŸ”¬. His expertise also extends to chronic wound healing, including diabetic foot, pressure ulcers, and non-healing surgical wounds 🦢🩹. Additionally, Dr. Wang is proficient in surgical treatments for superficial tumors and scar carcinoma, performing skin grafts and flap reconstructions with precision and care πŸ§«πŸ”§.

Professional Affiliations πŸ₯

Dr. Kun Wang holds esteemed positions across numerous national and regional medical associations, showcasing his influential role in burn and wound care research and practice 🩺🌐. He is a committee member in key organizations such as the Chinese Medical Association, Chinese Association of Integrative Medicine, and the Chinese Association of Plastic and Aesthetics πŸ‡¨πŸ‡³πŸ§¬. Regionally, he serves as Vice Chairman and Chairman in multiple Shandong and Weifang medical societies, including those focused on tissue regeneration, plastic surgery, and disaster medicine πŸ§‘β€βš•οΈπŸ§ͺ. His professional affiliations reflect his dedication to advancing collaborative, interdisciplinary healthcare and research nationwide 🀝πŸ₯.

Research Focus πŸ”¬

Dr. Kun Wang’s research focus centers on advanced wound healing technologies, particularly in diabetic patients 🧫🩹. His work highlights the development of multifunctional dressings, such as those incorporating curcumin, which demonstrate powerful anti-inflammatory, antioxidant, angiogenic, and collagen-regenerating properties 🌿πŸ§ͺ. These innovations aim to enhance tissue repair, accelerate healing, and reduce complications in chronic wounds like diabetic ulcers 🦢πŸ”₯. By merging traditional Chinese medicine with modern biomedical science, Dr. Wang contributes significantly to improving patient outcomes in burn and wound care πŸ”¬β€οΈβ€πŸ©Ή. His research plays a vital role in next-generation therapies for complex and non-healing wounds.

Publication πŸ“„

Paper Title: Multi-functional dressing with curcumin displays anti-inflammatory, antioxidant, angiogenic, and collagen regeneration effects in diabetic wound healing
Authors: Dr. Kun Wang, et al.
Journal: Journal of Wound Care

Prof Yuri Lyubchenko | Biomaterials | Best Researcher Award

Prof Yuri Lyubchenko | Biomaterials | Best Researcher Award

Prof. Yuri Lyubchenko πŸŽ“πŸ§¬ is a globally renowned biophysicist and nanotechnologist whose groundbreaking research spans neurodegenerative diseases 🧠, cancer biology 🧫, HIV research πŸ§ͺ, and nanoimaging πŸ”¬. With advanced degrees in Chemical Kinetics, Molecular Biophysics, and Molecular Biology, he pioneered the on-surface aggregation mechanism for amyloids and developed high-resolution AFM techniques to probe biomolecular structures at the nanoscale. 🧿 A Distinguished Scientist at UNMC 🌟, Prof. Lyubchenko has over 200 publications and has served on major NIH, NSF, and DOE panels. His innovative work continues to reshape our understanding of human disease and molecular biology on a global scale. 🌍✨

Prof Yuri Lyubchenko, University of Nebraska Medical Center, United States

Profile

GOOGLESCHOLAR

πŸŽ“ Education

Prof. Yuri Lyubchenko’s academic journey began at the prestigious Moscow Institute of Physics and Technology πŸ‡·πŸ‡Ί, where he earned an M.S. in Chemical Kinetics βš—οΈ in 1968. He then advanced to a Ph.D. in Molecular Biophysics 🧬 by 1971, and later crowned his academic accomplishments with a D.Sc. in Molecular Biology 🧫 in 1989 at the Institute of Molecular Genetics, Moscow. This exceptional educational foundation laid the groundwork for a pioneering career in biomedical research, empowering him to tackle complex biological questions with atomic-level precision and innovation. πŸŒπŸ“šβœ¨

πŸ… HonorsΒ 

In 2008, Prof. Yuri Lyubchenko was honored as a Distinguished Scientist πŸ† at the University of Nebraska Medical Center, acknowledging his remarkable contributions to biomedical research. His service to the scientific community spans across elite institutionsβ€”he has served on NIH study sections, NCI intramural research panels, as well as NSF and DOE review boards πŸ§ͺπŸ“Š. As an associate and academic editor ✍️ for over a dozen high-impact journals, he continues to shape scientific discourse worldwide. His leadership, credibility, and dedication make him a pillar in the global research ecosystem 🌐🧠.

🧬 Research Leadership

Prof. Yuri Lyubchenko has held a series of impactful roles across top-tier institutions worldwide. Since 2004, he has served as Professor at the University of Nebraska Medical Center 🏫. His earlier appointments include key research positions at Arizona State University πŸ”¬ and the University of Nevada Reno πŸŒ„. Prior to his U.S. appointments, he led pioneering molecular biology work at the USSR Academy of Sciences πŸ‡·πŸ‡Ί. From junior scientist to senior leadership roles, his journey through academia and global research centers reflects an extraordinary legacy of commitment, discovery, and innovation in the life sciences 🌟πŸ§ͺ.

πŸ”¬ Research Focus

Prof. Yuri Lyubchenko’s research is at the forefront of structural biology, focusing on the mechanistic regulation of DNA-protein interactions, chromatin dynamics, and amyloid aggregationβ€”key to understanding neurodegenerative diseases 🧠. He has revolutionized the application of atomic force microscopy (AFM) 🧫 for nanoscale visualization of DNA, RNA, and protein complexes in various environments 🌊. His work on beta-amyloid aggregation and PARP-1 regulation has been widely cited, reflecting a lasting impact on neuroscience and molecular genetics πŸ“ˆ. Prof. Lyubchenko’s research bridges nanotechnology with biology, offering transformative tools and perspectives for biomedical science βš™οΈπŸ§ͺ.

πŸ“˜ Publications

Regulation of poly (ADP-ribose) polymerase-1 by DNA structure-specific binding
πŸ‘¨β€πŸ”¬ I. Lonskaya, V.N. Potaman, L.S. Shlyakhtenko, E.A. Oussatcheva, Y.L. Lyubchenko, et al.
πŸ§ͺ Journal of Biological Chemistry, 280 (17), 17076–17083 (2005)
πŸ“Š Citations: 265
🧬🧠 DNA Repair | Protein Interaction | Structural Biology

Β Atomic force microscopy imaging of double-stranded DNA and RNA
πŸ‘¨β€πŸ”¬ Y.L. Lyubchenko, A.A. Gall, L.S. Shlyakhtenko, R.E. Harrington, B.L. Jacobs, et al.
πŸ§ͺ Journal of Biomolecular Structure and Dynamics, 10 (3), 589–606 (1992)
πŸ“Š Citations: 252
πŸ”¬πŸ§¬ Visualization | AFM | Molecular Structure

Atomic force microscopy of DNA and bacteriophage in air, water and propanol: the role of adhesion forces
πŸ‘¨β€πŸ”¬ Y.L. Lyubchenko, P.I. Oden, D. Lampner, S.M. Lindsay, K.A. Dunker
πŸ§ͺ Nucleic Acids Research, 21 (5), 1117–1123 (1993)
πŸ“Š Citations: 232
🧲🦠 DNA Imaging | Nanotechnology | Surface Chemistry

Residues 17–20 and 30–35 of beta‐amyloid play critical roles in aggregation
πŸ‘¨β€πŸ”¬ R. Liu, C. McAllister, Y. Lyubchenko, M.R. Sierks
πŸ§ͺ Journal of Neuroscience Research, 75 (2), 162–171 (2004)
πŸ“Š Citations: 229
🧠🧩 Alzheimer’s Disease | Protein Aggregation | Amyloids

πŸ” 5. Comparative studies of bacteria with an atomic force microscopy operating in different modes
πŸ‘¨β€πŸ”¬ A.V. Bolshakova, O.I. Kiselyova, A.S. Filonov, O.Y. Frolova, Y.L. Lyubchenko, et al.
πŸ§ͺ Ultramicroscopy, 86 (1–2), 121–128 (2001)
πŸ“Š Citations: 226
πŸ¦ πŸ”¬ Bacteria | AFM Techniques | Surface Analysis

AFM for analysis of structure and dynamics of DNA and protein–DNA complexes
πŸ‘¨β€πŸ”¬ Y.L. Lyubchenko, L.S. Shlyakhtenko
πŸ§ͺ Methods, 47 (3), 206–213 (2009)
πŸ“Š Citations: 222
πŸ”¬πŸ§¬ DNA-Protein Interactions | Method Development | AFM

Dr Binod Dhakal | Biomaterials | Best Researcher Award

Dr Binod Dhakal | Biomaterials | Best Researcher Award

Dr. Binod Dhakal is an esteemed hematologist-oncologist πŸ©ΈπŸŽ—οΈ and Associate Professor at the Medical College of Wisconsin πŸ₯. He holds an M.D. from Saint Francis Hospital and an MBBS from Manipal College of Medical Sciences, with an M.S. in Clinical & Translational Science. His research focuses on multiple myeloma, CAR-T cell therapy, and cancer immunotherapy 🧬. Dr. Dhakal has secured multimillion-dollar grants πŸ’°, received prestigious awards πŸ…, and serves as a reviewer for leading oncology journals πŸ“–. His contributions to oncology research and education make him a top contender for the Best Researcher Award.

Dr Binod Dhakal, Medical College of Wisconsin, United States

Profile

GOOGLESCHOLAR

SCOPUS

EducationπŸŽ“

Dr. Binod Dhakal has an impressive academic journey in medicine and oncology πŸ₯πŸ”¬. He earned his MBBS from Manipal College of Medical Sciences, Nepal πŸ‡³πŸ‡΅ (1999-2004) and later completed his M.D. at Saint Francis Hospital, Evanston, IL, USA πŸ‡ΊπŸ‡Έ (2007-2010). He specialized further as a Hematology/Oncology Fellow at the Medical College of Wisconsin (2013-2016) πŸ©ΈπŸŽ—οΈ. To strengthen his research expertise, he obtained an M.S. in Clinical & Translational Science from the Clinical and Translational Institute of Southeast Wisconsin (2015-2016) πŸ“ŠπŸ§¬. His extensive education underscores his commitment to advancing cancer research and patient care.

Awards and Honors πŸ†

Dr. Binod Dhakal is a highly acclaimed hematologist-oncologist πŸŽ—οΈ, recognized for his excellence in medical research and education πŸ“š. He has received numerous prestigious awards, including the American Society of Oncology Travel Trainee Award ✈️, Best Oral Abstract Award πŸ…, and Outstanding Medical Student Teacher Award 🏫. His leadership was further acknowledged as Chief Fellow in Hematology/Oncology πŸ₯. Dr. Dhakal’s groundbreaking work in multiple myeloma and cancer immunotherapy 🧬 has earned him esteemed fellowships and research accolades. His dedication to advancing oncology and mentoring future physicians makes him a leading figure in the field.

Contributions πŸ‘¨β€πŸ«

Dr. Binod Dhakal is a dedicated mentor and faculty leader, guiding numerous fellows and researchers in multiple myeloma studies 🩸🧬. Since 2016, he has mentored Guru Subramaniam in research and MS thesis development. His mentorship extends to esteemed fellows like Smith Giri (2018-Present), Madan Aryal (2018-2022), Lindsay Hammons (2021-2023), and Ramsha Ahmed (2022-Present) πŸ“šπŸ”. His contributions continue with Bicky Thapa, Gulrayz Ahmed, Ravi Narra, Jennifer Obasi, Othman Akhtar, Fumou Sun, and Kritika Yadav, ensuring future advancements in hematology and oncology. His commitment to training the next generation of experts solidifies his impact in medical research.

Books Chapters πŸ“–

Dr. Binod Dhakal has made significant contributions to medical literature through books, chapters, and editorial works πŸ“šπŸ“. His 2011 piece, Medical Student Perspectives: Journey Through Different Worlds, explores user-driven healthcare. He co-authored statistical analysis discussions in Current Concepts and Controversies in Hematopoietic Cell Transplantation (2014) πŸ“ŠπŸ“–. His works on allogeneic stem cell transplantation and CAR-T therapy in multiple myeloma (2015-2020) in Bone Marrow Transplantation and Blood Reviews provide crucial insights into hematology and oncology 🩸🧬. His expertise in narrative medicine, stem cell therapy, and cancer research continues to shape the field.

Research Focus πŸ”¬

Dr. Binod Dhakal’s research primarily focuses on multiple myeloma, hematopoietic cell transplantation (HCT), and CAR-T cell therapy πŸ§¬πŸ§‘β€βš•οΈ. His work explores stem cell mobilization with novel induction therapies, B-cell maturation antigen (BCMA)-directed immunotherapy, and cytokine release syndrome in HCT patients πŸ’‰πŸ¦ . He has investigated the role of beta-blockers like propranolol in reducing molecular risk markers and examined the ethical challenges in CAR-T cell therapy slot allocation βš–οΈπŸ”. His research provides groundbreaking insights into improving transplant success rates and reducing treatment-related complications, shaping the future of oncology and hematology. πŸš€πŸ“š

Publications πŸ“š

“Cilta-cel or standard care in lenalidomide-refractory multiple myeloma” πŸ§¬πŸ’Š
πŸ–Š Authors: J. San-Miguel, B. Dhakal, K. Yong, A. Spencer, S. Anguille, M.V. Mateos, et al.
πŸ“– Journal: New England Journal of Medicine πŸ₯
πŸ“… Year: 2023
πŸ“Š Citations: 400

“Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma (OPTIMISMM): a randomised, open-label study” πŸ’‰πŸ”¬
πŸ–Š Authors: P.G. Richardson, A. Oriol, M. Beksac, A.M. Liberati, M. Galli, F. Schjesvold, et al.
πŸ“– Journal: The Lancet Oncology πŸ₯
πŸ“… Year: 2019
πŸ“Š Citations: 400

“Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma” 🦠🩸
πŸ–Š Authors: L.J. Costa, S. Chhabra, E. Medvedova, B.R. Dholaria, T.M. Schmidt, K.N. Godby, et al.
πŸ“– Journal: Journal of Clinical Oncology πŸ₯
πŸ“… Year: 2022
πŸ“Š Citations: 220

“Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis” πŸ₯πŸ“Š
πŸ–Š Authors: B. Dhakal, A. Szabo, S. Chhabra, M. Hamadani, A. D’Souza, S.Z. Usmani, et al.
πŸ“– Journal: JAMA Oncology 🩺
πŸ“… Year: 2018
πŸ“Š Citations: 187